Lombard Medical Technologies (NSDQ:EVAR) said this month that its CEO Simon Hubbert and CFO William Kullback are stepping down from their positions, with Kurt Lemvigh stepping into the CEO role.
Hubbert served as CEO for 6 years after joining the company in 2010, and will be replaced by Lemvigh, who has held positions with multiple companies, including Cardiac Science and GE (NYSE:GE).
“Lombard represents a unique opportunity given the strength of the company’s portfolio in the over $1.5 billion market for endovascular repair products. The key to success will be our ability to leverage the work that has been done over the years and moreover, to achieve operational excellence. For my part, I am committed to creating value for all of the stakeholders of Lombard,” Lemvigh said in a prepared statement.
“Simon made many significant contributions during his six years as CEO of Lombard including expanding the company’s product portfolio and geographic reach. On behalf of the board and shareholders, we thank Simon for his contributions and diligent efforts during a time of significant change in the endovascular aneurysm repair market. We wish him well in his future endeavors,” board chair Raymond Cohen said in a press release.
Kullback’s resignation was part of the company’s discontinuation of commercial operations in the US, the company said, and not the result of any disagreements with the company. Kullback will be moving on to “pursue a new opportunity at a San Diego, Calif.-based company,” according to an SEC filing.
Becton Dickinson & Co. (NYSE:BDX) said this week it tapped current exec vice chair and medical segment prez Tom Polen as its new company president.
With the shift, Polen will oversee all of BD’s operating segments, including medical, life sciences and the new interventional segment formed when it agreed to pick up Bard in a $24 billion deal.
“Tom brings a deep understanding of BD, the medical technology industry and the global healthcare environment. His well-deserved promotion reflects his leadership in developing and implementing BD Medical’s strategy and vision, his proven track record of delivering strong performance, and his commitment to ensuring the ongoing success of BD and its associates. I look forward to continuing to work closely with the Board, Tom, our entire leadership team, and our associates to successfully integrate and grow the combined company in the years ahead, as we deliver on our purpose of advancing the world of health,” CEO & chair Vince Forlenza said in a press release.
“This is an exciting time for BD. I am honored to serve in this new role as we continue our transformation into a medical technology leader focused on delivering solutions that advance the discovery, diagnostics and delivery of health care globally and helping health care providers worldwide to improve both the process of care and the treatment of disease,” Polen said in a prepared statement.
USGI Medical said last week it appointed ex-ConMed (NSDQ:CNMD) exec Carlos Babini as its new president and CEO.
Prior to his position as head of USGI, Babini served as VP of AirSeal system commercialization at ConMed, chief commercialization officer at Surgiquest and various other executive positions in medtech.
“I am delighted to join USGI Medical at this critical time as the company continues to establish the Pose procedure as a credible option for clinicians who have patients seeking clinical assistance to achieve weight loss. This procedure has the potential to help millions of obese patients globally who have not been able to keep weight off through diet and exercise alone, and who may not be candidates for, nor able to undertake the possible risks associated with invasive bariatric surgery,” Babini said in a prepared statement.
“I have had the pleasure of working with Mr. Babini during this initial period and in a very short time, already experienced positive momentum and engagement with the entire USGI team,” former CEO & current exec chair Scott Moonly said in a press release.
Fresenius (NYSE:FMS) has tapped Telefonica Deutschland finance chief Rachel Empty as its new chief financial officer, according to German business monthly Manager Magazin.
Fresenius CEO Sturm, who was promoted to CFO last June, said earlier this week that the company had found someone for its CFO position, but did not clarify when their current employer would let them go.
Negotiations for the move are in their final stage, the magazine said. A spokesperson for Fresenius would not comment on the report.
Boston Scientific (NYSE:BSX) said last week that exec VP, chief administrative officer, general counsel and secretary Timothy Pratt will retire from the company at the end of the year.
Pratt jointed Boston Scientific in May 2008 as an exec VP, GC and secretary. Over the next several months, Pratt said he intends to lead the effort to find a successor and aid in a transition to the new GC.
- Magnolia Medical taps Gerberich as CCO
- Accuracy appoints Hadjadjeba as senior VP, CCO
- ReWalk Robotics names Gricci as CCO
- Toshiba Medical picks Skyba as ultrasound biz director
- Senseonics taps Gill as sales VP
The post Lombard Medical CEO Hubbert, CFO Kullback step down | Personnel Moves, April 28, 2017 appeared first on MassDevice.
from MassDevice http://ift.tt/2peqzW7
The North American Free Trade Agreement may not be facing the gallows after the Trump administration this week said it does not plan to terminate it – but changes to the deal could have a huge impact on the medical device industry, according to a New York Times report.
A pilot study evaluating an artificial pancreas in children with Type I diabetes found that the device helped kids control their condition, according to researchers at the 
Shares in 
Angioplasty is not a new procedure – doctors have been widening obstructed arteries with balloons since the 1960s. But for years the medtech industry has been plagued with what Jeff Mirviss, president of Boston Scientific’s interventional peripheral biz, calls the procedure’s Achilles heel: Restenosis.
Baxter chairman & CEO Joe Almeida says he’s prepared to pull the trigger on a major acquisition worth as much as $7.5 billion, but any deal has to pass the healthcare giant’s M&A criteria.
The U.S. Defense Dept. yesterday awarded a 
Shares in 
South Korea regulators said today that it fined Swiss drugmaker 
Researchers at the